Christoph Heuck, Vice President Clinical Research at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on LinkedIn:
“The Tecvayli team has achieved another significant milestone in our mission to advance transformative treatment options for patients with multiple myeloma. Congratulations to the MajesTEC-9 team on the recent study results, which demonstrated a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death for patients treated with Tecvayli monotherapy compared to the standard of care in relapsed/refractory multiple myeloma.
Kudos to Priya Shah, Katherine Chastain, Rachel Kobos, Robin Carson, and their team for their dedication to driving this study to a successful outcome.
A Special thanks to the MajesTEC-9 investigators whose expertise ensured the program’s success, and to the patients who participated in MajesTEC-9—their partnership makes progress possible.
This achievement marks an important step forward in delivering innovative therapies to those in need.”
More posts featuring Christoph Heuck.